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Aims: Preference-based measures have been derived from various condition-specific descriptive 
HRQOL measures. A general 2-stage method has evolved: 1) an item from each domain of the 
HRQOL measure is selected to form a health state classification system (HSCS); 2) a sample of health 
states is valued and an algorithm derived for estimating the utility of all possible health states. 
Building on preliminary work with the cancer-specific QLQ-C30, the aim of this analysis was to 
further adapt the first stage, in particular to incorporate confirmatory rather than exploratory factor 
analysis (CFA, EFA).  
Methods: Data were collected with the QLQ-C30v3 from 356 patients receiving radiotherapy for 
recurrent or metastatic cancer (various primary sites). The dimensional structure of the QLQ-C30 
was tested with EFA and CFA, the latter based on a conceptual model (the established domain 
structure of the QLQ-C30: physical, role, emotional, social and cognitive functioning, plus several 
symptoms) and clinical judgment. The dimensions determined by each method were then subjected 
to statistical scrutiny, including Rasch analysis.  
Results: CFA results generally supported the proposed conceptual model, with residual correlations 
suggesting minor adjustments (namely, introduction of two cross-loadings) to improve model fit 
(increment chi-squared(2) = 77.78, p < .001). Although EFA revealed a structure similar to the CFA, 
some items had loadings that were difficult to interpret. Further assessment of dimensionality with 
Rasch analysis aligned the EFA dimensions more closely with the CFA dimensions. Three items 
exhibited floor effects (>75% observation at lowest score), 6 exhibited misfit to the Rasch model (fit 
residual > 2.5), none exhibited disordered item response thresholds, 4 exhibited DIF by gender and 
cancer site, and 3 symptoms were considered relatively less clinically important than the remaining 
9.  
Conclusions: CFA is more appropriate than EFA in this case, given the well-established structure of 
the QLQ-C30 and its clinical relevance. Further, the confirmatory approach produced more 
interpretable results than the exploratory approach. Other aspects of the general method remain 
largely the same. The revised method will be applied to a large number of pooled data sets as part of 
the international and interdisciplinary multi-attribute utility instrument in cancer (MAUCa) project 
